P1NP (procollagen type-1 N-propeptide)
The recommended blood marker of bone formation. When bone-building cells make new collagen, they release a fragment called P1NP, so its level reflects how much new bone is being laid down. It is used mainly to check whether osteoporosis treatment is working.
What it measures
New bone is built on a scaffold of type-1 collagen, made by osteoblasts (bone-building cells). As they produce collagen, a small piece is snipped off and released into the blood — the procollagen type-1 N-propeptide, or P1NP. Its level therefore mirrors the rate of bone formation. P1NP is the internationally recommended reference marker of bone formation (paired with CTX as the reference marker of bone breakdown), because it is relatively stable and specific to bone. Its most important practical use is monitoring osteoporosis treatment. When a person starts an anti-resorptive drug (such as a bisphosphonate), P1NP falls within a few months — an early sign the medicine is working, and a way to check that a person is taking it and absorbing it, well before a repeat bone-density scan could show change. With bone-building (anabolic) treatments such as teriparatide, P1NP instead rises, confirming the drug is stimulating new bone. Higher P1NP also reflects generally high bone turnover — as in Paget's disease, an overactive parathyroid, healing fractures, and normal growth. It is a monitoring and turnover tool, interpreted with density scans and other markers rather than used to diagnose osteoporosis by itself.
What a high value can mean
- High bone formation / turnover — as in Paget's disease or an overactive parathyroid.
- A rise on anabolic osteoporosis treatment (e.g. teriparatide) — the expected response, showing new bone is being built.
- Healing fractures — active bone building.
- Growth — normally high in children and adolescents.
- Bone metastases — from certain cancers.
What a low value can mean
- A fall on anti-resorptive treatment (e.g. a bisphosphonate) — the desired response, and a check of adherence and absorption.
- Suppressed bone formation — such as with long-term steroid treatment.
When to discuss with a doctor
P1NP is used mainly to monitor osteoporosis treatment rather than to diagnose it. A baseline is taken before starting therapy; a follow-up value a few months later shows whether an anti-resorptive drug has lowered bone turnover as expected (or an anabolic drug has raised formation), giving an early, practical check of whether treatment is working and being taken correctly — long before a repeat density scan. Levels vary with age, sex, kidney function and time of day, so results are interpreted against the individual's baseline and alongside CTX, density scans, calcium and vitamin D. Mediora.AI shows P1NP alongside the other bone markers so the formation-and-breakdown pattern is visible; the interpretation and any treatment decisions belong with your doctor.